Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine

Lawrence Einhorn, S. D. Williams, E. E. Stevens, W. H. Bond, L. Chenoweth

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD). Fifteen patients had Stage IV disease and 11 had systemic symptoms. Although hematologic toxicity was considerable, there was no drug related mortality. Eight patients achieved a complete remission (CR), and five are currently in a continuous CR of five, 24, 30, 34, and 36 months duration, respectively. An additional patient had a 30-month CR and relapsed with localized lymphadenopathy and is currently disease-free following involved-field radiotherapy 46 months from initiation of VABCD. This study suggests that long-term disease-free survival and potential cure can be achieved with VABCD in MOPP-refractory Hodgkin's disease.

Original languageEnglish
Pages (from-to)1348-1352
Number of pages5
JournalCancer
Volume51
Issue number8
DOIs
StatePublished - 1983

Fingerprint

Lomustine
Dacarbazine
Vinblastine
Bleomycin
Hodgkin Disease
Doxorubicin
Procarbazine
Mechlorethamine
Vincristine
Therapeutics
Prednisone
Combination Drug Therapy
Disease-Free Survival
Radiotherapy
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine. / Einhorn, Lawrence; Williams, S. D.; Stevens, E. E.; Bond, W. H.; Chenoweth, L.

In: Cancer, Vol. 51, No. 8, 1983, p. 1348-1352.

Research output: Contribution to journalArticle

Einhorn, Lawrence ; Williams, S. D. ; Stevens, E. E. ; Bond, W. H. ; Chenoweth, L. / Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine. In: Cancer. 1983 ; Vol. 51, No. 8. pp. 1348-1352.
@article{ebbfda7f5e42408b8ada5c3237fa91c5,
title = "Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine",
abstract = "Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD). Fifteen patients had Stage IV disease and 11 had systemic symptoms. Although hematologic toxicity was considerable, there was no drug related mortality. Eight patients achieved a complete remission (CR), and five are currently in a continuous CR of five, 24, 30, 34, and 36 months duration, respectively. An additional patient had a 30-month CR and relapsed with localized lymphadenopathy and is currently disease-free following involved-field radiotherapy 46 months from initiation of VABCD. This study suggests that long-term disease-free survival and potential cure can be achieved with VABCD in MOPP-refractory Hodgkin's disease.",
author = "Lawrence Einhorn and Williams, {S. D.} and Stevens, {E. E.} and Bond, {W. H.} and L. Chenoweth",
year = "1983",
doi = "10.1002/1097-0142(19830415)51:8<1348::AID-CNCR2820510804>3.0.CO;2-7",
language = "English",
volume = "51",
pages = "1348--1352",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine

AU - Einhorn, Lawrence

AU - Williams, S. D.

AU - Stevens, E. E.

AU - Bond, W. H.

AU - Chenoweth, L.

PY - 1983

Y1 - 1983

N2 - Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD). Fifteen patients had Stage IV disease and 11 had systemic symptoms. Although hematologic toxicity was considerable, there was no drug related mortality. Eight patients achieved a complete remission (CR), and five are currently in a continuous CR of five, 24, 30, 34, and 36 months duration, respectively. An additional patient had a 30-month CR and relapsed with localized lymphadenopathy and is currently disease-free following involved-field radiotherapy 46 months from initiation of VABCD. This study suggests that long-term disease-free survival and potential cure can be achieved with VABCD in MOPP-refractory Hodgkin's disease.

AB - Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD). Fifteen patients had Stage IV disease and 11 had systemic symptoms. Although hematologic toxicity was considerable, there was no drug related mortality. Eight patients achieved a complete remission (CR), and five are currently in a continuous CR of five, 24, 30, 34, and 36 months duration, respectively. An additional patient had a 30-month CR and relapsed with localized lymphadenopathy and is currently disease-free following involved-field radiotherapy 46 months from initiation of VABCD. This study suggests that long-term disease-free survival and potential cure can be achieved with VABCD in MOPP-refractory Hodgkin's disease.

UR - http://www.scopus.com/inward/record.url?scp=0020661466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020661466&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19830415)51:8<1348::AID-CNCR2820510804>3.0.CO;2-7

DO - 10.1002/1097-0142(19830415)51:8<1348::AID-CNCR2820510804>3.0.CO;2-7

M3 - Article

C2 - 6186356

AN - SCOPUS:0020661466

VL - 51

SP - 1348

EP - 1352

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -